Coya Therapeutics Inc. announced positive results from an investigator-initiated proof-of-concept open-label study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with Frontotemporal Dementia (FTD). Over a 22-week treatment period, the study demonstrated enhanced regulatory T cell (Treg) numbers and function, as well as cognitive stability as measured by CDR-FTLD and Montreal Cognitive Assessment (MOCA) scores. The most common adverse event was mild erythema at the injection site, with no serious adverse events reported. The results have already been presented. Coya Therapeutics plans to advance the combination, COYA 302, into a phase 2 clinical trial for FTD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108513635) on January 08, 2026, and is solely responsible for the information contained therein.